본문으로 건너뛰기
← 뒤로

Risk of Newly Incident Diabetes Mellitus and Treatment Risk Factors in Breast Cancer Survivors: Landmark Analyses of Nationwide Data.

코호트 1/5 보강
Asia-Pacific journal of public health 2026 p. 10105395261433225
Retraction 확인
출처

Shim H, Kim BS, Han K, Koo HY, Kim S, Lee D, Cho IY, Jung W, Shin DW

📝 환자 설명용 한 줄

This study investigated temporal patterns and risk factors for diabetes mellitus (DM) in breast cancer survivors, stratified by age.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 연구 설계 cohort study

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Shim H, Kim BS, et al. (2026). Risk of Newly Incident Diabetes Mellitus and Treatment Risk Factors in Breast Cancer Survivors: Landmark Analyses of Nationwide Data.. Asia-Pacific journal of public health, 10105395261433225. https://doi.org/10.1177/10105395261433225
MLA Shim H, et al.. "Risk of Newly Incident Diabetes Mellitus and Treatment Risk Factors in Breast Cancer Survivors: Landmark Analyses of Nationwide Data.." Asia-Pacific journal of public health, 2026, pp. 10105395261433225.
PMID 41937258

Abstract

This study investigated temporal patterns and risk factors for diabetes mellitus (DM) in breast cancer survivors, stratified by age. Using a Korean database, this nationwide cohort study analyzed 65 982 breast cancer survivors and 168 214 matched controls. We assessed DM risk using multivariable Fine-Gray models with landmark analyses, stratifying by age (≤50 and >50 years). Diabetes mellitus risk peaked in the first year post-diagnosis for women ≤50 (sub-distribution hazard ratio [sHR] = 3.74; 95% confidence interval CI [3.08, 4.55] and >50 (sHR = 1.71; 95% CI [1.52, 1.93], with risk diminishing thereafter. Significant risk factors included high body mass index, smoking, hypertension, dyslipidemia, and taxane use. Tamoxifen was a specific risk factor for younger women (sHR = 1.22; 95% CI [1.06, 1.40]). Breast cancer survivors, especially younger women, have the highest DM risk within the first year post-diagnosis. Proactive monitoring is crucial for those with established clinical and treatment-related risk factors.